Interstitial pneumonia with autoimmune features show better survival and less exacerbations compared to idiopathic pulmonary fibrosis

Jeong Uk Lim1,3, Bo Mi Gil2, Hye Seon Kang3, Jongyeol Oh3, Yong Hyun Kim3* and Soon Seog Kwon3

Abstract

Background: Patients with interstitial lung disease (ILD) who show features related to autoimmunity without meeting criteria for a defined connective tissue disease are categorized as interstitial pneumonia with autoimmune features (IPAF). The present study compared clinical characteristics and clinical outcomes of patients with IPAF to patients with connective tissue disease related-interstitial lung disease (CTD-ILD) and patients with idiopathic pulmonary fibrosis (IPF).

Methods: ILD patients who were consecutively enrolled in a single institution ILD cohort between 2008 and 2015 were evaluated for the study. Clinical data had been prospectively collected, while radiologic imaging and pathologic findings were re-reviewed for the present study.

Results: Out of 305 patients with ILD, 54 (17.7%) patients met the classification of IPAF, 175 (57.4%) patients had IPF, and 76 (24.9%) patients were diagnosed with CTD-ILD. Compared to IPF, incidences of acute exacerbations in 1, 3 and 5 years were significantly less in the IPAF group (p = 0.022, p = 0.026 and p = 0.007, respectively). From multivariate analysis for mortality, age (p = 0.034, HR 1.022, 95% CI: 1.002–1.044), FVC (p < 0.001, HR 0.970, 95% CI: 0.955–0.984), ILD exacerbation (p = 0.001, HR 2.074, 95% CI: 1.366–3.148), and ILD type (p = 0.047, HR 0.436, 95% CI: 0.192–0.984 (IPAF vs IPF), respectively) showed significant association.

Conclusions: Compared to the other ILD groups, IPAF showed distinct clinical characteristics. The IPAF group showed better survival and less episodes of exacerbation when compared to the IPF group.

Keywords: Interstitial pneumonia with autoimmune features, Interstitial lung disease, Connective tissue disease, Idiopathic pulmonary fibrosis
From the study by Oldham et al., the IPAF cohort showed worse survival than the CTD-ILD group, while showing slightly better survival than the idiopathic pulmonary fibrosis (IPF) group [3]. The study by Ahmad et al. found no significant difference between IPAF and IPF [7].

However, in order to recommend the classification of IPAF for wider use among clinicians, more clinical data needs to be accumulated. A series of studies on IPAF were published after the expert consensus in 2015, however, little is known about longitudinal clinical outcomes of IPAF, and the question whether IPAF has better survival than IPF remains to be answered. Furthermore, the acute exacerbation (AE) of ILD has been reported to be a significant negative prognostic factor associated with worse survival in CTD-ILD and IPF [8–10]. Nevertheless, it has not been evaluated for IPAF in previous studies.

In the present study, we compared clinical characteristics, survival and ILD exacerbation of IPAF patients to the CTD-ILD and IPF groups, from the ILD cohort of a single institution.

Method
Patient selection
ILD patients who were consecutively enrolled at the time of diagnosis between 2008 and 2015 were evaluated. Clinical data was collected prospectively in this ILD cohort. Our institution has a longitudinal ILD cohort and the clinical and laboratory data of patients in this cohort have been collected prospectively using an ILD-pre-specified protocol. Databases were collected on a regular basis and in real-time at the time of work up. For the present study, data has been retrospectively reviewed, while radiologic imaging and pathologic findings were re-reviewed by radiologists and pathologists.

According to the European Respiratory Society/American Thoracic Society research statement on IPAF, 54 patients were categorized into the IPAF group [1]. All CTD-ILD patients had been referred to rheumatologists before diagnosis. Clinical characteristics and overall survival of the IPAF patients were compared to those of CTD-ILD patients and IPF patients. For comparison of clinical characteristics, the IPF group was further categorized into seronegative and seropositive IPF subgroups.

IPAF criteria
The diagnosis of IPAF was done following the European Respiratory Society/American Thoracic Society research statement [1]. The patients’ clinical data, laboratory, radiologic and histopathologic findings were evaluated to check whether they met the criteria of clinical, serologic and morphologic domains. After exclusion of other possible causes, such as malignancy or heart failure, initial HRCT images were checked for features of multi-compartment involvement such as unexplained pericardial effusion, and pleural effusion and thickening. Unexplained intrinsic airways disease was defined as never smokers with forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio of <70%. We defined it as such, as similar findings in ever-smokers would mean a possibility of concurrent chronic obstructive pulmonary disease [11]. Pulmonary vasculopathy was determined by the presence of pulmonary hypertension (PH) defined as a mean pulmonary artery pressure ≥ 25 mmHg via right heart catheterization (RHC) [1]. RHC is the gold standard diagnostic method for the diagnosis of PH, but we did not perform RHC routinely as this is an invasive procedure [12]. In the present study, findings coherent to high right ventricular load detected on trans-thoracic Doppler echocardiography [13] or FVC/diffusing capacity for carbon monoxide (DLco) > 1.6 and DLco < 60% were used as criteria for the definition of pulmonary hypertension [1, 3, 14]. In order to exclude the possibility of an overlap with CTD-ILD, all our potential IPAF patients were seen by rheumatologists.

Time to first exacerbation
AE of non-IPF ILD groups and IPF group were defined using the revised definition of IPF proposed in 2016 [15]. There is, however, no existing official definition of AE-ILD in non-IPF ILD [16]. Time duration between enrolment to the cohort and first ILD exacerbation was estimated. An exacerbation of ILD was defined as a patient being admitted to the hospital due to acute aggravation of ILD occurring less than 1 month before admission [15].

Seropositive IPF
Patients with IPF who presented with positive features of the serologic domain, but without any features of the clinical and morphologic domains of IPAF were classified as the seropositive IPF. Patients with IPF who did not have positive features of the serologic domain of IPAF were classified as seronegative IPF.

Statistical analysis
For comparison of continuous variables between the groups, one-way analysis of variance (ANOVA) was performed, and chi-squared test was used to compare categorical variables. Overall survival (OS) was estimated from the time of enrolment in the cohort until death of any cause. Kaplan-Meier curve analysis and log-rank test were used to compare duration of survival between the groups. For survival analysis, cox regression hazard model was used to evaluate association between mortality and the clinical variables. The factors which were
significant in the univariate analysis were entered into a multivariate Cox regression model to determine their independent effects. Statistical significance was established at a \( P \)-value of 0.05.

**Ethical statement**
This retrospective study was approved by the Institutional Review Board of Bucheon St Mary’s Hospital. The need for informed consent was waived because the study was a retrospective review.

**Results**

**IPAF characterization**
Among 305 patients evaluated, 54 (17.7%) patients met the classification of IPAF. Table 1 shows detailed features within each domain of IPAF patients. A total of 17 (31.5%) patients showed features coherent with the criteria of the clinical domain. Arthralgia was the most common symptom (76.5%), followed by Raynaud's phenomenon and unexplained digital oedema (both 16.7%). Among 54 IPAF patients, 49 (90.7%) patients met the criteria of the serologic domain. ANA abnormality was the most common finding (63.3%), followed by high rheumatoid factor levels and positive anti-cyclic citrullinated peptide (anti-CCP) (14 (28.6%) and 7 (14.3%) patients, respectively). A total of 44 (81.5%) patients met the morphologic domain criteria. Among the 39 patients with features of the morphologic domain, 34 (87.2%) patients showed NSIP patterns on HRCT findings, which was the most common ILD pattern in the IPAF group. Three (7.7%) patients presented with organizing pneumonia. Among 34 patients who underwent diagnostic biopsy, 12 patients showed histopathologic patterns consistent with features of the morphologic domain. In 5 patients, interstitial lymphoid aggregates with germinal centres were the most common finding (41.7%) among patients with histopathologic patterns related to IPAF, followed by pathologic findings consistent with organizing pneumonia (4 patients, 33.3%). Findings defined as multi-compartment involvement were seen in 11 (20.4%) patients; unexplained pleural effusion or thickening in 5 (45.5%) patients, unexplained pericardial effusion or thickening in 3 (27.3%) patients, unexplained intrinsic airways diseases in 2 (18.2%) patients and unexplained pulmonary vasculopathy in 1 (9.1%) patient.

**Comparison of clinical characteristics between IPAF, CTD-ILD and seronegative/seropositive IPF**
Clinical characteristics of the IPAF patients were compared to 76 CTD-ILD, 145 seronegative IPF and 30 seropositive IPF (Table 2) patients. The CTD-ILD group was comprised of 46 patients with rheumatoid arthritis (RA), 18 patients with systemic sclerosis, 6 patients with Sjogren’s syndrome, 5 patients with

---

**Table 1**: Autoimmune features of 54 IPAF patients according to criteria and domains

| Domain                        | Frequency |
|-------------------------------|-----------|
| **Clinical domain (n = 17)**  |           |
| Distal digital fissuring      | 1 (5.9)   |
| Distal digital tip ulcerations| 0 (0)     |
| Inflammatory arthritis or polyarticular morning joint stiffness ≥60 min | 13 (76.5) |
| Palmar telangiectasia         | 0 (0)     |
| Raynaud's phenomenon          | 3 (17.6)  |
| Unexplained digital oedema    | 3 (17.6)  |
| Unexplained fixed rash on the digital extensor surface | 0 (0) |

| Domain                        | Frequency |
|-------------------------------|-----------|
| **Serologic domain (n = 49)** |           |
| ANA ≥1:320 titer, diffuse, speckled or homogeneous patterns, ANA nucleolar pattern (any titer), or ANA centromere pattern (any titer) | 31 (63.3) |
| Rheumatoid factor > 2x upper limit of normal | 14 (28.6) |
| Anti-CCP                      | 7 (14.3)  |
| Anti-dsDNA                    | 3 (6.1)   |
| Anti-Ro (SS-A)                | 4 (8.2)   |
| Anti-La (SS-B)                | 1 (2.0)   |
| Anti-topoisomerase (Scl-70)   | 1 (2.0)   |
| Anti-ribonucleoprotein        | 2 (4.1)   |
| Anti-Smith                    | 2 (4.1)   |
| Anti-tRNA synthetase, Anti-Pm-Scl, Anti-MDA-5 | 0 (0) |

| Domain                        | Frequency |
|-------------------------------|-----------|
| **Morphologic domain (n = 44)** |           |
| Suggestive radiology patterns by HRCT | 39 (72.2) |
| Nonspecific interstitial pneumonia | 34 (87.2) |
| Organising pneumonia          | 3 (7.7)   |
| Nonspecific interstitial pneumonia with organising pneumonia overlap | 2 (5.1) |
| Lymphoid interstitial pneumonia | 0 (0) |
| Histopathologic pattern       | 12 (22.2) |
| Nonspecific interstitial pneumonia | 0 (0) |
| Organising pneumonia          | 4 (33.3)  |
| Nonspecific interstitial pneumonia with organising pneumonia overlap | 1 (8.3) |
| Intersitial lymphoid aggregates with germinal centres | 5 (41.7) |
| Diffuse lymphoplasmacytic infiltration | 2 (16.7) |
| Multi-compartment involvement (in addition to interstitial pneumonia) | 11 (20.4) |
| Unexplained pleural effusion or thickening | 5 (45.5) |
| Unexplained pericardial effusion or thickening | 3 (27.3) |
| Unexplained intrinsic airways diseases | 2 (18.2) |
| Unexplained pulmonary vasculopathy | 1 (9.1) |

Abbreviations: HRCT high-resolution computed tomography scan, IPAF interstitial pneumonia with autoimmune features

*Percentages show the proportions of positive findings among each subdomain in which they are included (suggestive radiology patterns by HRCT, histopathologic pattern, and multi-compartment involvement)
inflammatory muscle disease and 1 patient with systemic lupus erythematous (SLE).

The proportion of male (35.2%) patients was significantly lower in the IPAF group than in both the seronegative and seropositive IPF groups ($p < 0.001$, 71.0 and 73.3%, respectively), but similar to that of the CTD-ILD (31.2%) group. Mean age and the proportion of ever smokers was significantly lower in both the IPAF and CTD-ILD groups than in the seronegative and seropositive IPF ($p < 0.001$ and $p < 0.001$, respectively).

There was a significant difference between the groups for ILD patterns observed on the initial HRCT ($p < 0.001$). In the IPF group, 100% of the patients presented with UIP patterns on HRCT and no radiological NSIP pattern was noted. Usual interstitial pneumonia (UIP) pattern on the initial HRCT was seen in 25.9% of the IPAF group and 46.1% of the CTD-ILD group. The NSIP pattern was the most frequent ILD pattern observed in the IPAF group (63%). While only 22.4% of the CTD-ILD group showed the NSIP pattern, which was the second most frequent pattern after UIP. Emphysematous change was seen in only 9.3% of the IPAF group, which is lower than in the CTD-ILD group, and the seropositive and seronegative IPF groups ($p = 0.006$).

In the IPAF group, 63% of the patients underwent diagnostic biopsy, which was the highest proportion among the four groups ($p < 0.001$). There was no difference in spirometric parameters between the four groups.

### Table 2 Comparison of clinical characteristics between IPAF, CTD-ILD and IPF

|                     | IPAF      | CTD-ILD   | Seronegative IPF | Seropositive IPF |
|---------------------|-----------|-----------|------------------|------------------|
| Sex (male) (n, %)   | 19 (35.2) | 24 (31.6) | 103 (71.0)       | 22 (73.3)        |
| Mean age (SD)       | 67.9 ± 10.5 | 61.6 ± 13.5 | 71.6 ± 9.5       | 71.8 ± 8.3        |
| Ever smoker (n, %)  | 15 (27.8) | 23 (30.3) | 95 (65.5)        | 20 (66.7)        |
| Smoking pack years | 7.0 ± 14.9 | 11.1 ± 20.4 | 24.6 ± 23.1      | 26.7 ± 32.1      |
| ILD pattern from HRCT |         |           |                  |                  |
| UIP                 | 14 (25.9) | 35 (46.1) | 145 (100)        | 30 (100)         |
| NSIP                | 34 (63.0) | 17 (22.4) | 0 (0)            | 0 (0)            |
| OP                  | 3 (5.6)   | 5 (6.6)   | 0 (0)            | 0 (0)            |
| NSIP + OP           | 2 (3.7)   | 3 (3.9)   | 0 (0)            | 0 (0)            |
| UIP                 | 0 (0)     | 2 (2.6)   | 0 (0)            | 0 (0)            |
| Emphysema from HRCT (n, %) | 5 (9.3) | 17 (22.4) | 45 (31.0)        | 9 (30)           |
| Lung biopsy at diagnosis $^a$ |         |           |                  |                  |
| None                | 20 (37.0) | 33 (43.4) | 86 (59.3)        | 14 (46.7)        |
| TBLB                | 13 (24.1) | 11 (14.5) | 38 (26.2)        | 12 (40)          |
| VATS                | 25 (46.3) | 21 (27.6) | 18 (12.4)        | 9 (30)           |
| FVC, L              | 2.4 ± 0.7 | 2.6 ± 0.8 | 2.5 ± 0.8        | 2.8 ± 0.9        |
| FVC (% of predicted) | 81.8 ± 17.0 | 86.2 ± 18.4 | 80.7 ± 19.1 | 83.8 ± 17.6       |
| FEV1, L             | 1.9 ± 0.6 | 2.0 ± 0.6 | 2.0 ± 0.6        | 2.2 ± 0.7        |
| FEV1/FVC            | 82.0 ± 7.7 | 79.1 ± 9.4 | 82.1 ± 8.9       | 79.9 ± 9.6       |
| TLC, L              | 3.8 ± 12  | 4.1 ± 10  | 4.4 ± 14         | 4.5 ± 13         |
| TLC (% of predicted) | 87.8 ± 21.6 | 91.1 ± 18.7 | 91.6 ± 24.5 | 84.5 ± 19.0       |
| VCL                 | 2.4 ± 0.7 | 2.6 ± 0.8 | 2.7 ± 0.8        | 2.8 ± 0.9        |
| VC (% of predicted) | 84.5 ± 17.7 | 87.4 ± 19.5 | 80.6 ± 19.2 | 82.0 ± 18.3       |
| DLCO (absolute)     | 10.6 ± 4.4 | 10.6 ± 3.6 | 11.4 ± 6.0       | 9.7 ± 4.4        |
| DLCO (% of predicted) | 62.7 ± 21.0 | 62.3 ± 18.2 | 68.5 ± 24.3 | 57.9 ± 19.0       |

Abbreviations: CTD-ILD connective tissue disease-related interstitial lung disease, DLCO Diffusing capacity of the lungs for carbon monoxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, HRCT high-resolution computed tomography scan, ILD interstitial lung disease, IPAF interstitial pneumonia with autoimmune features, IPF idiopathic pulmonary fibrosis, LIP lymphocytic interstitial pneumonia, NSIP nonspecific interstitial pneumonia, OP organizing pneumonia, SD standard deviation, TBLB transbronchial lung biopsy, TLC total lung capacity, UIP usual interstitial pneumonia, VATS video-assisted thoracoscopic surgery, VC vital capacity

$^a$Some patients underwent multiple diagnostic procedures
ILD exacerbations

During the observation period, AE-ILD was seen in 25.9% of the IPAF group, 32.9% of the CTD-ILD and 35.4% of the IPF group ($p < 0.001$). The proportions of patients who experienced exacerbations were significantly different in 1, 3 and 5 years after enrolment in the cohort ($p = 0.022$, $p = 0.026$ and $p = 0.007$, respectively). When time to first exacerbation was compared between the groups, the IPAF group showed no significant difference compared to the IPF group, while the CTD-ILD group showed a significantly longer duration compared to the IPF group ($p = 0.02$). Mean value of time to first exacerbation was $29.5 \pm 27.5$ months in the IPAF group, $32.6 \pm 29.7$ months in the CTD-ILD group and $17.3 \pm 21.4$ months in the IPF group (Table 3).

Survival analysis

OS was compared between the different combinations of ILD types. Mean survival time was 73.3 months in the IPAF group, 104.0 months in the CTD-ILD, 50.7 months in the seronegative IPF group, and 56.5 months in the seropositive IPF group. Difference on OS among the four groups was statistically significant ($p < 0.001$) (Fig. 1). When the seronegative and seropositive IPF groups were combined into a single group, a significant difference in OS of the three groups was seen as well ($p < 0.001$) (Table 3) (Fig. 2), with a mean survival time of 52.0 months in the IPF group. When the IPAF patients with UIP pattern ($n = 15$) were compared to the IPF group, OS was slightly better in the IPAF than in the IPF group (64.6 months vs 52.0 months, respectively), with no significant difference ($p = 0.08$) (Fig. 3).

For analysis of association with mortality, the following variables - age, gender, smoking history, autoimmune antibody positivity, first line treatment, emphysema from HRCT, FVC, DLCO, ILD exacerbation and ILD type, were entered in the univariate analysis. Age, gender, smoking history, autoimmune antibody positivity, FVC, DLCO, ILD exacerbation and ILD type were significant factors from the univariate analysis, and were entered in the multivariate analysis. Age, FVC, ILD exacerbation and ILD type were significant risk factors for mortality in the multivariate analysis ($p = 0.034$, HR 1.022, 95% CI: 1.002–1.044; $p < 0.001$, HR 0.970, 95% CI: 0.955–0.984; $p = 0.001$, HR 2.074, 95% CI: 1.366–3.148; $p = 0.047$, HR 0.436, 95% CI: 0.192–0.984 (IPAF vs IPF), respectively). From the multivariate analysis, the IPAF type was associated with significantly better survival when compared to the IPF (Table 4).

Table 3 Comparison of clinical outcomes between IPAF, CTD-ILD and IPF

|                | IPAF ($n = 54$) | CTD-ILD ($n = 76$) | IPF ($n = 175$) | $P$-value* |
|----------------|-----------------|--------------------|-----------------|------------|
| Total deaths during observation | 15 (27.8%)      | 16 (21.1%)         | 111 (63.4%)     | $< 0.001^{ab}$ |
| Mean survival time (months)      | 73.3 ± 6.6      | 104.0 ± 6.7        | 52.0 ± 3.6      | $< 0.001^{ab}$ |
| Time to first exacerbation (mean, months) | 29.5 ± 27.5    | 32.6 ± 29.7        | 17.3 ± 21.4     | 0.02a       |
| ILD exacerbations                |                 |                    |                 |            |
| Whole observation period         | 14 (25.9%)      | 25 (32.9%)         | 62 (35.4%)      | $< 0.001^{b}$ |
| 5 yr                           | 11 (21.1%)      | 19 (25.3%)         | 56 (33.5%)      | 0.007a     |
| 3 yr                           | 9 (17.3%)       | 15 (20.0%)         | 47 (28.1%)      | 0.026a     |
| 1 yr                           | 6 (11.5%)       | 9 (12.0%)          | 37 (22.0%)      | 0.022a     |

Abbreviations: CTD-ILD connective tissue disease-related interstitial lung disease, ILD interstitial lung disease, IPAF interstitial pneumonia with autoimmune features, IPF idiopathic pulmonary fibrosis

*Statistical difference between the three groups

aSignificant statistical difference between CTD-ILD and IPF

bSignificant statistical difference between IPAF and IPF

Discussion

We applied the definition of IPAF in patients with ILD from the cohort at our institution, and further compared clinical characteristics and clinical outcomes of this cohort to patients with CTD-ILD and IPF from the same institution. Our study has its strength in comparing longitudinal clinical outcomes, including ILD exacerbation between the different ILD groups. In the present study, IPAF showed distinct clinical characteristics when compared to other ILD types. In addition, the IPAF group showed better survival and less exacerbation events when compared to the IPF group.

Of the three domains of the IPAF criteria, features of the serologic domain was most commonly observed (90.7%), thereafter, features of the morphologic domain (81.5%). This is different from the results of a previous study by Yoshimura et al. in which features of the morphologic domain was most commonly observed (96.9%), followed by the serologic domain [17], and consistent with the results of the study on IPAF by Ahmad et al. [7].

When baseline clinical characteristics were compared, the IPAF group in our study showed some similarities to
previous studies. In our study, NSIP was the most frequent HRCT pattern, which was consistent with previous studies [7, 17]. Idiopathic NSIP is often associated with autoimmune features [6], and a high proportion of NSIP in the IPAF group suggests a possible correlation with autoimmune features.

Furthermore, the percentage of female patients was more than 50% for both the IPAF group and the CTD-ILD group. A female predominance in the IPAF group of our study is consistent with results of previous publications [5, 6]. However, Ahmad et al. demonstrated a slight male predominance in the IPAF group as well as the IPF group (female percentage 49%) [7]. Regarding smoking history, our study showed a lower proportion of ever smokers than previous studies. (27.8% vs 34.8 and 38.8%) [7, 18].

In addition to comparison of baseline clinical characteristics, our study focused on longitudinal clinical outcomes of IPAF: AE-ILD and mortality. First, the proportions of patients who experienced exacerbations in the IPAF group at different time periods were significantly lower when compared to the IPF group. Moreover, despite statistical insignificance, the time to first exacerbation in the IPAF group was longer than that of the IPF group. In IPF, AE-ILD is a known significant negative prognostic factor [8], and was found to be a significant factor associated with mortality in our multivariate analysis.

Secondly, our study demonstrated that the IPAF group showed significantly better survival than the IPF group. Ahmad et al. showed that there was no significant difference in OS between patients with IPAF and patients with IPF [7]. In addition, Oldham et al. showed that there was no statistically significant difference in OS between the IPAF and IPF cohort. On the other hand, both studies by Ahmad et al. and Oldham et al. showed that the survival of patients with IPAF was not better than that of patients with CTD-ILD [3, 7].

The finding that the IPAF group showed better survival compared to the IPF group should be considered in conjunction with the difference in ILD exacerbation incidence and proportion of UIP pattern observed on the initial HRCT. We first hypothesized that ILD exacerbation would be the major factor contributing to the difference of overall survival between the ILD groups, because AE-ILD is a strong negative prognostic
Furthermore, compared to the IPF group, the proportion of patients who experienced AEs was significantly less in the IPAF group and this difference in proportion was repeatedly shown in year 1, 3 and 5. In addition, IPAF was independently associated with better survival compared to IPF, with other factors such as AE-ILD also adjusted in the analysis. However, the definition of AE in IPF was also applied to non-IPF groups in the present study [14], and this may have affected the analysis. Further studies, including more detailed evaluation of AEs in non-IPF ILD are needed to clarify other intrinsic factors associated with survival in IPAF.

We initially assumed that the proportion of UIP pattern observed on HRCT would influence the clinical outcome, because the UIP pattern has been reported to be associated with worse survival [19, 20]. In our study, survival comparison between the 15 IPAF patients with UIP pattern and the IPF group showed no significant difference ($p = 0.08$). The IPAF group tends to have a longer survival duration than the IPF group, however, the difference was not statistically significant. We believe that a future prospective study focusing on comparing these two specific subgroups may give a clearer comparative result.

We also attempted to compare the IPAF group to groups of other ILD types with different levels of autoimmune features. When the diagnostic criteria of IPAF were first recommended by ATS/ERS, they focused on ILD with autoimmunity, not meeting established criteria of CTD [1]. From our study, the IPAF group showed some clinical findings similar to CTD-ILD, such as sex, smoking history and time to first exacerbation. We believe that the similarities came from autoimmune tendencies shared by the two disease entities. Furthermore, IPAF patients should be placed under longitudinal surveillance for future occurrence of CTD [18, 21]. We think that patients who were categorized as IPAF at the time of initial diagnostic work up, should be reevaluated on a regular basis for the possibility of definitive CTD-ILD. We also compared clinical characteristics of the IPAF group to the IPF group with seropositivity,

![Kaplan-Meier analysis](image.png)
Fig. 3 Survival was compared between the IPAF patients with UIP pattern (n = 15) and the IPF group (n = 175). No significant difference was present (p = 0.08).

Table 4 Variables analyses for prediction of mortality in the study patients

| Characteristics                  | Univariate     |            |          |          | Multivariate |            |          |          |
|----------------------------------|----------------|------------|----------|----------|--------------|------------|----------|----------|
|                                  | P   | HR   | 95% CI   |          |              | P   | HR   | 95% CI   |
| Age                              | <0.001 | 1.035 | 1.018–1.052 |          |              | 0.034 | 1.022 | 1.002–1.044 |
| Male/Female                      | 0.011 | 1.563 | 1.106–2.210 |          |              | 0.945 | 0.976 | 0.493–1.934 |
| Smoking history                  | 0.032 | 1.463 | 1.034–2.071 |          |              | 0.110 | 1.758 | 0.879–3.513 |
| Positive autoimmune Ab           | <0.001 | 0.498 | 0.347–0.714 |          |              | 0.433 | 0.804 | 0.467–1.386 |
| First line treatment             | 0.549 |    |            |          |              |          |        |          |
| Systemic corticosteroid          |        |    |            |          |              |          |        |          |
| Antifibrotics                    |        | 1.417 | 0.453–4.432 |          |              |          |        |          |
| Emphysema from HRCT              | 0.514 | 1.132 | 0.780–1.642 |          |              |          |        |          |
| FVC (%)                          | <0.001 | 0.964 | 0.954–0.975 | <0.001 | 0.970 | 0.955–0.984 |
| DLCO (%)                         | <0.001 | 0.978 | 0.969–0.988 | 0.051 | 0.988 | 0.976–1.000 |
| ILD exacerbation (yes/no)        | 0.003 | 1.654 | 1.180–2.317 | 0.001 | 2.074 | 1.366–3.148 |
| ILD type                         | <0.001 | 1     |            |          |              | 0.039 | 1     |          |
| IPF                              |        | 0.470 | 0.269–0.821 | 0.047 | 0.436 | 0.192–0.990 |
| IPAF                             |        | 0.235 | 0.135–0.410 | 0.026 | 0.401 | 0.179–0.898 |

Abbreviations: Ab antibody, CTD-ILD connective tissue disease-related interstitial lung disease, DLCO Diffusing capacity of the lungs for carbon monoxide, FVC forced vital capacity, HRCT high-resolution computed tomography scan, ILD interstitial lung disease, IPAF interstitial pneumonia with autoimmune features, IPF idiopathic pulmonary fibrosis
considering the possibility that the latter group may have some autoimmune features. However, the seropositive IPF group showed no clinical similarities with the IPAF and the CTD-ILD groups in terms of sex, smoking history, radiologic findings and clinical outcomes. In addition, the seropositive IPF group did not show distinct clinical characteristics from the seronegative IPF group. Despite the serologic findings, we believe that the IPAF group and IPF group with autoimmune antibody share little similarity in clinical characteristics.

IPAF is a relatively recently defined disease category of ILD, and the applicability of the criteria has been repeatedly discussed [21–23]. From our study, arthralgia and Raynaud’s phenomenon were the two most common findings among the criteria of the clinical domain. This finding was similar to a previous study [7]. However, distal digital fissuring (“mechanic’s hands”), unexplained fixed rash on the digital extensor surfaces (Gottron’s sign), and distal digital tip ulceration were absent or less frequent signs in our study. We assume that some findings related to the clinical domain are more suggestive of CTD rather than fulfilling the diagnostic criteria for IPAF. As was suggested by Ahmad et al., these signs often lead to the diagnosis of CTD after referral to rheumatologists [7]. On the other hand, there were 10 patients from our ILD cohort who showed dry mouth or eye symptoms and also showed seropositivity or radiologic/histopathologic findings coherent to the morphologic domain of IPAF, but not fulfilling the diagnostic category of IPAF. Dry eye or dry mouth are clinical symptoms related to Sjögren’s disease [24]. Such symptoms are subjective, because they are non-visual findings and can vary depending on patients’ general condition. However, the symptoms of dry eye and dry mouth can be clinically relevant if other rheumatologic findings are present and should be checked for relevance to autoimmune features. We think that clinical findings such as dry eye or dry mouth could be carefully considered for inclusion into the clinical domain if concurrent autoimmune features are present.

The present study has some limitations. First, this is a single institution retrospective study, and the possibility of selection bias exists. However, the study patients were enrolled consecutively and many of the previous studies were also single institution-based studies [5, 7]. Secondly, categories other than CTD-ILD and IPF were not included in the study. CTD-ILD and IPF were two major ILD categories in our ILD cohort, while cases of disease such as hypersensitivity pneumonitis and sarcoidosis were not sufficient in number for comparison. In addition, we focused on the two groups (CTD-ILD and IPF), as they show different levels of autoimmune tendencies [15, 16]. Lastly, the treatment data in our study included only antifibrotics and short-term systemic steroids, and did not include detailed analysis of other treatment modalities such as lung transplant or immunosuppressives. In addition, baseline comorbidities of patients were not described. We think that a future study including more detailed treatment data and comorbidities is necessary.

**Conclusion**

The IPAF group showed distinct clinical characteristics. In terms of ILD exacerbation and mortality, the IPAF group showed better clinical outcomes when compared to the IPF group. Further prospective studies are necessary to clarify the essential clinical features of IPAF before applying the disease category for clinical use.

**Abbreviations**

AE: Acute exacerbation; ANOVA: One-way analysis of variance; Anti-CCP: Anti-cyclic citrullinated peptide; CTD-ILD: Connective tissue disease related-interstitial lung disease; DLCO: Diffusing capacity for carbon monoxide; FEV1/FVC: Forced expiratory volume in one second/forced vital capacity; HRCT: High resolution computed tomography; ILD: Interstitial lung disease; IPAF: Interstitial pneumonia with autoimmune features; IPF: Idiopathic pulmonary fibrosis; NSIP: Non-specific interstitial pneumonia; OS: Overall survival; PH: Pulmonary hypertension; RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; UCTD-ILD: Undifferentiated-CTD interstitial lung disease; UIP: Usual interstitial pneumonia

**Acknowledgements**

We want to acknowledge Dr. Ji-Won Min for English proofreading.

**Authors’ contributions**

All authors have read and approved the manuscript. JUL contributed to study design, data acquisition and manuscript drafting. BMG, HSK and JO contributed to data acquisition. SSK contributed to data analysis and interpretation. YHK contributed to data interpretation and manuscript revision.

**Funding**

The authors declare that no funding was received for this work.

**Availability of data and materials**

JUL and YHK are the guarantor of the content of this article, including the data and the analysis. All the data and the materials are available upon reasonable request.

**Ethics approval and consent to participate**

This retrospective study was approved by the Institutional Review Board of Bucheon St Mary’s Hospital. The need for informed consent was waived because the study was a retrospective review.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Division of Pulmonary and Critical Care Medicine, Department of Medicine, The Armed Forces Capital Hospital, Seongnam, South Korea. 2Department of Radiology, Bucheon St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, South Korea. 3Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 327, Sosa-ro, Bucheon-si, Gyeonggi-do 14647, Republic of Korea.
References

1. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–87.

2. Chung JH, Montner SM, Adegunsoye A, Lee C, Oldham JM, Hussain AN, MacWahon H, Noth I, Viu R, Strek ME. CT findings, radiologic-pathologic correlation, and imaging predictors of survival for patients with interstitial pneumonia with autoimmune features. AJR Am J Roentgenol. 2017;208(6):1229–36.

3. Oldham JM, Adegunsoye A, Valenz E, Lee C, Witr L, Chen L, Husain AN, Montner S, Chung JH, Cottin V, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016;47(6):1767–75.

4. Ferri C, Manfredi A, Sebastiani M, Colaci M, Giuggioli D, Vacchi C, Della Casa G, Cerri S, Torricelli P, Luppi F. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. Autoimmun Rev. 2016(15):151–61.

5. Charrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A. Clinical features and natural history of interstitial pneumonia with autoimmune features: a single center experience. Respir Med. 2016;119:150–4.

6. Dij J, Wanger L, Yan X, Li H, Zhou K, He J, Meng F, Xu S, Liang G, Cai H. Clinical features, risk factors, and outcomes of patients with interstitial pneumonia with autoimmune features: a population-based study. Cln Rheumatol. 2018;37(8):2125–32.

7. Ahmad K, Barba T, Gamondes D, Ginoux M, Khouatra C, Spagnolo P, Strek M, Thivolet-Bejui F, Tractel J, Cottin V. Interstitial pneumonia with autoimmune features: clinical, radiologic, and histologic characteristics and outcome in a series of 57 patients. Respir Med. 2017;123:56–62.

8. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–43.

9. Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, Hashizume H, Naito T, Hashimoto D, Takehara Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009;103(8):846–53.

10. Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ, Colby TV. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132(1):214–20.

11. Kono M, Nakamura Y, Enomoto N, Hashimoto D, Fujisawa T, Inui N, Maekawa M, Suda T, Colby TV, Chida K. Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One. 2014;9(4):e94775.

12. Bax S, Bredy C, Kempny A, Dimopoulos K, Oyama Y, Yasui H, Hozumi H, Hayama M, Suzuki Y, Funahashi K, et al. Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia. Respir Med. 2018;137:167–75.